Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib in Relapsed/Refractory Primary and Secondary CNS Lymphomas
NCT04548648Phase 2Active, not recruiting
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- Oct 2020
- Primary completion
- May 2025
- Countries
- 1
01
Overview
A Phase 2 trial of acalabrutinib tablet (Variant 1) in central nervous system lymphoma, sponsored by UNC Lineberger Comprehensive Cancer Center. Started Oct 2020; status: active, not recruiting.
02
Drugs
acalabrutinib tablet (Variant 1)
03
Conditions
central nervous system lymphoma
Beyond the preview
Go deeper on NCT04548648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04548648.